Prof. Dr. Ahmet Taner Sümbül
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Lung Neoplasms 9 publicationsSource: OpenAlex / PubMed MeSHView publications
- Neoplasms 8 publications
- Breast Neoplasms 8 publications
- Stomach Neoplasms 5 publications
- Carcinoma, Non-Small-Cell Lung 5 publications
- Adenocarcinoma 4 publications
- Liver Neoplasms 4 publications
- Colorectal Neoplasms 3 publications
- Carcinoma, Hepatocellular 3 publications
- Hypertension 2 publications
- Bile Duct Neoplasms 2 publications
- Cholangiocarcinoma 2 publications
- Mesothelioma, Malignant 2 publications
- Mesothelioma 2 publications
- Pleural Neoplasms 2 publications
- Brain Neoplasms 2 publications
- Carcinoma, Transitional Cell 2 publications
- Urologic Neoplasms 2 publications
- Urinary Bladder Neoplasms 2 publications
Person ↔ Disease
Which topics does this doctor work on?
Medical areas of interest stated by the doctor on the institution profile. Source: medicalpark.com.tr.
- Akciğer kanseri
- Meme kanseri
- Baş boyun kanseri
- Yumuşak doku tümörleri
- İmmunoterapi
- Hedefe yönelik tedavi
- Kemoterapi
- Destek tedavi
CV
Education and experience
Experience
- 20032008 Dr.Arş.Gör. Çukurova Üniversitesi İç Hastalıkları ADmedicalpark.com.tr
- 20092012 Dr.Arş.Gör. Yan Dal Başkent Üniversitesi Tıbbi Onkoloji BDmedicalpark.com.tr
- 20122014 M.K.Ü. Tıp Fakültesi İç Hastalıkları Tıbbi Onkoloji Bilim Dalı Başkanı Kemoterapi birimi ve Onkoloji Kliniği sorumlu hekimimedicalpark.com.tr
- 20122013 M.K.Ü. Tıp Fakültesi Hastanesi 2. Basamak Dahiliye Yoğun Bakım sorumlu hekimimedicalpark.com.tr
- 20122013 Uzm.Dr. Mustafa Kemal Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalımedicalpark.com.tr
- 20132014 Yrd.Doç.Dr. Mustafa Kemal Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalımedicalpark.com.tr
- 20152020 Doç.Dr. Başkent Üniversitesi Tıbbi Onkoloji BDmedicalpark.com.tr
- 20202023 Prof.Dr. Başkent Üniversitesi Tıbbi Onkoloji BD Medikal Park Adana Prof. Dr.medicalpark.com.tr
Education
- 199730.06.2003 Çukurova Üniversitesi Tıp Fakültesimedicalpark.com.tr
- 200304.11.2008 Çukurova Üniversitesi İç Hastalıkları Uzmanlıkmedicalpark.com.tr
- 200909.03.2012 Başkent Üniversitesi Tıbbi Onkoloji Yandal Uzmanlıkmedicalpark.com.tr
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- SpecialtyMedical Oncologymedicalpark.com.trFrom source
- Department name at the sourceMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trFrom source
- InstitutionMedical Park Seyhanmedicalpark.com.trFrom source
- Area of workLung NeoplasmsExtracted from 9 publications · Model version —From source
- Publications127 publicationsOpenAlex, ORCIDFrom source
- ORCID0000-0002-5573-906XORCIDFrom source
- Last synchronised4 November 2026 20:25https://www.medicalpark.com.tr/hekimler/ahmet-taner-sumbulmedicalpark.com.tr
Scientific work
Publications on Lung Neoplasms
-
Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study
Journal of Immunotherapy, 2026
DOI 10.1097/cji.0000000000000610 PMID 42267536 Source: OpenAlex
-
Adding immunotherapy to chemotherapy may improve survival after SCLC transformation in EGFR-mutant NSCLC: a multicenter real-world study
Lung Cancer, 2026
DOI 10.1016/j.lungcan.2026.109590 PMID 42664544 Open-access full textSource: ORCID
-
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study
JCO Oncology Practice, 2026
DOI 10.1200/op-25-01248 PMID 42234938 Open-access full textSource: OpenAlex
-
Real-life efficacy and safety data of lorlatinib treatment in ROS-1–positive advanced non-small cell lung cancer: Turkish Oncology Group (TOG) study.
Journal of Clinical Oncology, 2025
DOI 10.1200/jco.2025.43.16_suppl.e20659 Source: OpenAlex
-
The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).
Journal of Clinical Oncology, 2025
DOI 10.1200/jco.2025.43.16_suppl.e20501 Open-access full textSource: OpenAlex
-
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
Clinical Lung Cancer, 2025
DOI 10.1016/j.cllc.2025.07.015 PMID 40813186 2 citations (Europe PMC) Source: OpenAlex
-
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Medicina, 2025
DOI 10.3390/medicina61040638 PMID 40282929 5 citations (OpenAlex) Open-access full textSource: OpenAlex
-
Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
Journal of Chemotherapy, 2024
DOI 10.1080/1120009x.2024.2366683 PMID 38904164 1 citation (Europe PMC) Source: OpenAlex
-
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Scientific Reports, 2024
DOI 10.1038/s41598-024-56046-w PMID 38461209 16 citations (Europe PMC) Open-access full textSource: OpenAlex
-
46P The frequency of driver mutations in non-small cell cancer patients: Analysis of the 5064 patients in the Turkish nation-wide, observational, registurkLung study
ESMO Open, 2024
DOI 10.1016/j.esmoop.2024.102625 Open-access full textSource: OpenAlex